Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

119 results about "Platelet lysate" patented technology

Human platelet lysate (or hPL) is a substitute supplement for fetal bovine serum (FBS) in experimental and clinical cell culture. It is a turbid, light-yellow liquid that is obtained from human blood platelets after freeze/thaw cycle(s). The freeze/thaw cycle causes the platelets to lyse, releasing a large quantity of growth factors necessary for cell expansion. FBS-free cell culture media, e.g. with platelet lysate or chemically defined/ animal component free, are used for cell therapy or regenerative medicine. They are commercially available in GMP (good manufacturing practice)-quality which is generally basis for regulatory approval.

Mesenchymal stem cell self-preserving liquid

The invention discloses a mesenchymal stem cell self-preserving liquid which is prepared from the following raw materials according to volume ratios: 1-6% of self platelet lysate, 95-97% of solution medium and 0-1% of vitamin C injection, wherein the solution medium is a mixed sugar electrolyte injection or physiological saline injection. The mesenchymal stem cell self-preserving liquid has the advantages that: growth factors contained in the mesenchymal stem cell self-preserving liquid can maintain the activity state of cells, the vitamin C can maintain the activity of various peroxidases, at the same time, the mixed sugar electrolyte injection is especially suitable for cell preservation, and osmotic pressure is also favorable for nutrient absorption of the cells so as to carry out metabolism; the activity of the mesenchymal stem cells which are preserved in the mesenchymal stem cell self-preserving liquid within 8 hours is still larger than 90%, the cell activity change is not larger than 7%, and the activity of the mesenchymal stem cells which are preserved in the mesenchymal stem cell self-preserving liquid within 12 hours is still maintained at 85%; and by using the mesenchymal stem cell self-preserving liquid, the requirements for human intravenous back-transfusion safety can be met, and the cell preserving problem of long-time transport is solved, thus more patients have opportunity to undergo mesenchymal stem cell treatment.
Owner:CHENGDU QINGKE BIOTECH

Preparation method of serum-free freezing medium of human umbilical cord mesenchymal stem cells (hUC-MSCs)

The invention relates to the technical field of freezing mediums, and discloses a preparation method of a serum-free freezing medium of human umbilical cord mesenchymal stem cells (hUC-MSCs). The serum-free freezing medium of the hUC-MSCs is prepared from the following components in percentage by volume: 20-80% of a basal culture medium, 5-30% of platelet lysate, 1-10% of instant-dissolving protein polysaccharide mother liquor, and 5-25% of trehalose mother liquor. According to the preparation method of the serum-free freezing medium of the hUC-MSCs, the platelet lysate and trehalose are usedfor replacing original animal serum and DMSO, and thus the preparation method has the advantages that the activity of the UC-MSCs can be maintained for a long time, the survival rate of the cells is significantly increased, and preparation is easy and safe; and the problems that the DMSO serves as a permeating protective agent and can penetrate into the cells quickly, the time that the cells are exposed in the harmful environment is shortened, however, the DMSO has the toxic effect on the cells at the room temperature, operation at the room temperature needs to be quick as soon as possible, FBS can increase the probability of animal pathogenic pollution, and consequently, uncertain factors are added for future using of the cells are solved.
Owner:青岛麦迪赛斯生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products